At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 346 enrolled
Drug / intervention
Comparator: Rizatriptan +1 moredrug
Likely dose
Comparator: Rizatriptan 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Elimination of Migraine-Associated Nausea in Migraine Patients Treated With Rizatriptan Orally Disintegrating Tablet (ODT)
In Brief
A Phase 3 clinical trial evaluating Comparator: Rizatriptan and Comparator: Placebo for Migraine. Completed, enrolled 346 participants.
Detailed Summary
Study to test the effectiveness of a marketed drug in the treatment of migraine-associated nausea.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2005
Enrollment StartMar 2006
Primary CompletionOct 2006
TodayJul 2026
First PostedNov 8, 2005
Enrollment StartMar 1, 2006
Primary CompletionOct 1, 2006
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 20.7 years ago
Interventions
Comparator: Rizatriptandrug
One dose Rizatriptan 10 mg orally disintegrating tablet / oral lyophilisate to treat one migraine attack.
Comparator: Placebodrug
One dose matching placebo to Rizatriptan to treat one migraine attack.